The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Insights into the management of Burkitt lymphoma: the need to improve frontline treatment
Ariela Noy, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares insights into the management of Burkitt lymphoma, highlighting the importance of identifying the optimal backbone regimen and emphasizing the need to improve frontline treatment. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in Burkitt lymphoma, we’ve had a few studies that discussed frontline, and what we now know is, of course, the addition of rituximab makes a difference, but it’s not clear what the optimal backbone is. And so I did discuss some of that, showing that the CODOX-M/IVAC compared to the R-EPOCH, may be more toxic, but it’s not clear that it’s a better regimen. And we also looked at relapsed/refractory data, which is very abysmal...
So in Burkitt lymphoma, we’ve had a few studies that discussed frontline, and what we now know is, of course, the addition of rituximab makes a difference, but it’s not clear what the optimal backbone is. And so I did discuss some of that, showing that the CODOX-M/IVAC compared to the R-EPOCH, may be more toxic, but it’s not clear that it’s a better regimen. And we also looked at relapsed/refractory data, which is very abysmal. And we just published our series from MSK, which is similar to others, showing that almost no one survives if they have a relapse. So what we want to do is make a better improvement in the frontline setting. And I’m very excited because our study that incorporates adding a bispecific to the highest risk patients was sent to CTA for approval on Friday. So that protocol is now completely written and we’re hoping to activate it by the fourth quarter of 2025.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
